In line with the effects on PARP and caspase 3 cleavage, ABT199 treatment of the high BCL-2-expressing neuroblastoma cell lines resulted in more pronounced increases in sub-G1 fraction than observed for the low BCL-2-expressing cell lines (Figure 2B and Supplementary Table S1) Treatment with only 7.5 nmol/L ABT199 resulted in increases in sub-G1 fraction of 8% (CHP126), 13% (KCNR) and 5% (SJNB12) for the high BCL-2-expressing cell lines versus 0% (SKNAS) and 1% (SHEP2) for the low BCL-2-expressing cell lines. This evidence concerns the gene BCL2 and neuroblastoma.